Clinical Trials: 
It Doesn’t Need to be the “Same Old, Same Old”

Robert Hindes, MD
Chief Medical Officer and Co-Founder, TREK Therapeutics, PBC
Pharma experience includes BMS, Pharmasset, BeyondWest Pharma

Dr. Hindes did his Infectious Disease Fellowship at Harvard Medical School and New England Deaconess Hospital, after which he spent 12 years as a clinical and research infectious disease physician at Danbury Hospital and New York Medical College. Dr. Hindes co-founded Beyond West Pharmaceuticals to bring affordable drugs to developing countries, and has served as a consultant to several companies developing antiviral drugs.

Wednesday, September 21, 2016
Faculty Conference Room, S1-342
1st Floor Medical School
University of Massachusetts Medical School

4:00-5:00 pm LECTURE and CASE STUDY

Lecture and Case Study: This lecture will describe the familiar pre IND >>IND>>ph1>>ph2>>ph3>>NDA route for drug development in the U.S. The system is famous for being formulaic and slow to respond to new developments. Difficult questions will be discussed including whether placebo controlled studies are ethical, who should take the risk in compassionate access programs for desperate treatments seeking access to unapproved drugs and issues related to study size, market size and biomarkers. Dr. Hindes will describe examples where the FDA changed their approach in response to data and public pressure.

5:00-5:30 pm NETWORKING

Register Now!